bluuebunny/crossref_metadata_2025_split huggingface dataset:
Abstract P2-08-26: Cardiovascular events and mortality in a population-based cohort treated for ductal carcinoma in situ
Authors: Yoo Tae-Kyung , Chae Byung Joo , Han Kyung Do , Kim DaHye , Ahn Juneyoung , Park Woo-Chan , Oh Se Jeong 
Published: March 2020

Abstract
Background: Ductal carcinoma in situ (DCIS) patients are mostly diagnosed through cancer screening programs, suggesting that this population may have a healthy screenee effect of being more health-conscious, have lower comorbidity and belong to a higher socio-economic class. In this population-based cohort, we assessed the likelihood of cardiovascular events and mortality in DCIS patients, comparing with a control group of non-DCIS patients. Methods: Using the Korean National Health Insurance Service database, 13,740 women who were diagnosed of DCIS between 2007 and 2013 were analyzed. Control group matched by age was selected three times the number of DCIS cases (n=41,200). Follow-up for comorbidities and survival was performed up to 2016. Cox proportional hazard regression analysis was used to evaluate the association between DCIS and myocardial infarction (MI) risk, cerebrovascular stroke risk and mortality rate. The DCIS group was divided into pure DCIS patients and DCIS patients with subsequent invasive breast cancer for analysis. Results: Compared to the control group, patients with DCIS history were more likely to have hypertension, diabetes mellitus, dyslipidemia and the Charlson’s Comorbidity Index score was significantly higher. Patients with DCIS history also had higher income and were more likely to live in urban districts. Despite of higher comorbidity rate, pure DCIS patients had a trend of lower MI risk (HR 0.710; 95% CI 0.448 - 1.125) and significantly lower stroke risk (HR 0.708; 95% CI 0.492 - 1.019). Whereas, DCIS patients with subsequent invasive breast cancer had a significantly lower MI risk (HR 0.582; 95% CI, 0.371 - 0.913) and trend of lower stroke risk (HR 0.815; 95% CI 0.610 - 1.108). Mortality rate was similar between control group and pure DCIS patients, but was higher in DCIS patients with subsequent invasive breast cancer (HR 1.629; 95% CI 1.339 - 1.983). The trend of lower risk for cardiovascular events was sustained when adjusting for age, income and comorbidities (hypertension, diabetes mellitus and dyslipidemia). Conclusion: DCIS patients had a lower risk for MI and stroke compared to the control group despite of higher rate of comorbidities, which may reflect socioeconomic differences. DCIS patients with subsequent invasive breast cancer had higher mortality rate, whereas pure DCIS patients had similar survival rate compared to the control group.
Citation Format: Tae-Kyung Yoo, Byung Joo Chae, Kyung Do Han, DaHye Kim, Juneyoung Ahn, Woo-Chan Park, Se Jeong Oh. Cardiovascular events and mortality in a population-based cohort treated for ductal carcinoma in situ [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P2-08-26.
Abstract P2-09-03: Spectrum, prevalence and clinical outcomes of germline mutations in PALB2 genes in 16501 unselected BRCA1/2-negative breast cancer patients: A multi-center analysis
Authors: Zhou Jiaojiao , Wang Honglian , Fu Fangmeng , Li Zhanwen , Liu Yun , Feng Qingjian , Wu Weizhu , Wang Hongxia , Wang Chuan , Chen Yiding 
Published: March 2020

Abstract
Background: PALB2 (Partner and Localizer of BRCA2) is a breast cancer predisposition gene, which plays a critical role in homologous recombination via interacting with BRCA1/2 and RAD51 when DNA break. However, the clinical relevance of PALB2 germline mutations in Chinese breast cancer patients remains unknown. We attempted to illustrate the full prevalence and spectrum of PALB2 germline mutations in Chinese breast cancer population, and to investigate the clinical outcomes of PALB2 germline mutations. Patients and methods: A total of 21216 unselected breast cancer patients were enrolled from multiple clinical centers in China. After evaluation of the DNA quality and clinical information, 16501 eligible BRCA1/2-negative breast cancer patients were analyzed. A group of 5890 Chinese women without cancer was enrolled as healthy controls. PALB2 screening was based on next-generation sequencing, by screening complete coding sequence and intron-exon boundaries of PALB2. Clinical information was synchronously collected. Results: The 79 PALB2 deleterious germline mutations included 25 nonsense mutations, 47 frameshift mutations, and 7 splicing mutations. The hotspot region for PALB2 mutations was exon4. A total of 41 novel mutations were identified in PALB2. Among the 16501 BRCA1/2-negative breast cancer patients and 5890 healthy women, PALB2 deleterious mutation carriers account for 0.97% (n=160) and 0.19% (n=11) separately. PALB2 mutations were significantly associated with increased breast cancer risk (OR: 5.23, 95% CI 2.89-9.49; P&lt;0.0001), and especially in women aged 30 or younger (OR: 11.97, 95% CI 3.76-34.39; P&lt;0.0001). PALB2 mutation carriers were significantly more likely to be triple negative breast cancers and have bigger tumors, positive axillary lymph nodes, bilateral breast cancers, family history of breast and/or ovarian cancer and family history of any other cancer, than noncarriers. Conclusions: The PALB2 mutations confer a moderately increased breast cancer risk in women, but relatively highly increased breast cancer risk in those aged 30 or younger. PALB2 mutation status is associated with distinct clinical characteristics in breast cancer. Key words:PALB2, breast cancer, germline mutations, next-generation sequencing
Citation Format: Jiaojiao Zhou, Honglian Wang, Fangmeng Fu, Zhanwen Li, Yun Liu, Qingjian Feng, Weizhu Wu, Hongxia Wang, Chuan Wang, Yiding Chen. Spectrum, prevalence and clinical outcomes of germline mutations in PALB2 genes in 16501 unselected BRCA1/2-negative breast cancer patients: A multi-center analysis [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P2-09-03.
Abstract P2-09-10: Genetic variants of CCL5 signaling pathway genes in susceptibility and prognosis of triple negative breast cancers in Arab population
Authors: Al-Bader Salha Bujassoum , Shan Jingxuan , Bedognetti David , Chouchane Lotfi 
Published: March 2020

Abstract
Background:Triple-negative breast cancer (TNBC) has a higher rate of early relapse and mortality compared to other types of breast cancer (BC). CCL5 and its signaling pathway have been linked to TNBC. Methods:We characterized variants in CCL5and that of six other CCL5 signaling genes (CCND1, ZMIZ1, CASP8, NOTCH2, MAP3K21 and HS6ST3) among 1,082 unrelated Arab subjects, including 196 TNBC, accessed their association with BC-specific overall survival (OVS) and progression-free survival (PFS), and correlated CCL5 expression with CCL5genotypes. Results: CCND1 rs614367-TTgenotype was highly associated with the TNBC risk (OR = 5.14; P = 0.004) and the rs614367-Tallele was associated with decreased PFS in TNBC. A decreased risk of lymph node metastasis was associated with the MAP3K21rs1294255-C allele, particularly in rs1294255-GC (OR = 0.47; P = 0.001). CCL5variants (rs2107538and rs2280789) were linked to CCL5 serum and mRNA levels. In the TCGA TNBC/Basal-like cohort the MAP3K21rs1294255-G allele was associated with a decreased OVS. High expression of CCL5in breast tumors was significantly associated with an increased OVS in all BC patients, but particularly in TNBC/Basal-like patients. Conclusion:Genetic variation in CCL5 signaling genes may predict not only TNBC risk but also disease aggression.
Citation Format: Salha Bujassoum Al-Bader, Jingxuan Shan, David Bedognetti, Lotfi Chouchane. Genetic variants of CCL5 signaling pathway genes in susceptibility and prognosis of triple negative breast cancers in Arab population [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P2-09-10.
Abstract P2-10-17: Tissue prevalence and cellular heterogeneity of 9p24.1 amplification in TNBC in African American women
Authors: Anderson Karen S. , Naab Tammey , Koslosky Lori K , Anderson Megan , Lewis Michael , Kanaan Yasmine , Afsari Ali , Ricks-Santi Luisel , Pockaj Barbara A. , Barrett Michael T 
Published: March 2020

Abstract
Introduction: Amplification of chromosome 9p24.1 encoding PDL1, PDL2, and JAK2 (the PDJ amplicon) has been detected in 5-25% of triplenegative breast cancers (TNBC), and is associated with poor outcome and activation of the JAK/STAT pathway. Here, we have developed a robust multiplexed fluorescence in situ hybridization (FISH) assay for detection of 9p24.1 amplification, and assessed the frequency and cellular distribution of the PDJ amplicon in a cohort of African American (AA) women with TNBC. Methods: The FISH assay combines three chromosome 9 probes to simultaneously target JAK2 and PD-L1 (9p24.1, PDJ), chromosome 9q22, and the 9q34.1 regions. This enables discrimination of PDJ amplicons from whole chromosome 9p arm gains and from chromosome 9 ploidies that occur in the background of genomic instability in aneuploid cancer genomes. Fifty cells were scored for each probe and the average copy number was obtained. We defined PDJ amplification as PDJ&gt;4, PDJ/9q22 ratio≥2, and/or PDJ/9q34.1 ratio≥2. The assay was benchmarked to array CGH of flow sorted TNBC tissue from Mayo Clinic Arizona (n=14). Tissue microarrays from TNBC PDX tumors (n=20) and from African American women with TNBC (n=87) were assessed. Results: Using selected TNBC tissue with known CGH data, the FISH assay tightly correlated with PDJ copy number in 13/14 cases. The discordant case was negative by CGH on a biopsy with low tumor content, but FISH positive on tissue section (PDJ &gt;7.5 and a PDJ/9q22 ratio=4). Of 20 TNBC PDX tumors, 5 were amplified by FISH. Twelve of 87 (14%) of tumors had PDJ amplification by FISH, of which ten were from breast tissue and two were from lymph node. Of these 12, PDJ&gt;4 (n=0), PDJ/9q22 ratio≥2 (n=6), and PDJ/9q34.1 ratio≥2 (n=10). Significant intratumoral variation was observed with the presence of single cells with &gt;10 PDJ copies in 8/17 (47%) amplified and 0/90 non-amplified total cases. Conclusion: 9p24.1 (PDJ) amplification encoding JAK2, PD-L1, and PD-L2 is detected by three-color FISH in 14% of TNBC from African American women. Individual cells with ≥10 copies of PDJ was seen exclusively in 8/17 amplified cases. We identified 5 PDX tumors which may provide valuable preclinical models for the amplicon. The association of this biomarker with clinical outcome will be presented.
Citation Format: Karen S. Anderson, Tammey Naab, Lori K Koslosky, Megan Anderson, Michael Lewis, Yasmine Kanaan, Ali Afsari, Luisel Ricks-Santi, Barbara A. Pockaj, Michael T Barrett. Tissue prevalence and cellular heterogeneity of 9p24.1 amplification in TNBC in African American women [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P2-10-17.
Abstract P2-11-13: Specific aspect of utilization of the prognostic multigene assay for invasive lobular carcinoma at early stage: Oncotype Dx in the prospective French cohort PONDx
Authors: Douchet Gaëlle , Curtit Elsa , Bourgeois Hugues , Richard Sandrine , Zilberman Sonia , Mahi Younes , Gligorov Joseph 
Published: March 2020

Abstract
Introduction: Invasive lobular carcinoma (ILC) differs from invasive ductal carcinoma (IDC) in a number of biological features with possible implication in treatment choice particularly for adjuvant chemotherapy. Multigene assay are being used increasingly to guide therapy for endocrine responsive breast cancer without HER2 overexpression or amplification at early stage. But if their interest is well defined for IDC, there are few data for ILC. Our study examine the impact of a multigene assay, Oncotype Dx (ODx), for the population of lobular breast cancer. Patients and methods: It was a retrospectively analysis of a French prospective cohort of patients (PONDx), with use of ODx (n= 882 patients). We studied and compared the specifics aspects of the use and the results of ODx for the ILC ( n= 125 (14,2%)) and IDC patients (n= 691 (78.3%)). We took account of the clinicopathological features, the Recurrence Score (RS), resulting of ODx and its impact on decision making. Results: In our cohort ILC were more frequently grade 2 tumours, had a significantly larger size, and lower Ki67 than IDC. RS distribution was lower for ILC (p&lt;0,007): 66,4% of ILC had RS&lt;18, 28,8% had RS from 18 to 30 and 4,8% had RS&gt;30 ; whereas for IDC RS&lt;18 for 52,2%, RS 18-30 for 36,8% and RS&gt;30 for 11%. But there was a similar overall rate of change in treatment decision for ILC (46,4%) and IDC (43%) and a de-escalation of treatment (for no adjuvant chemotherapy) for 67,7% of ILC and 57,1% of IDC with initial indication of adjuvant chemotherapy. On the other hand, about 10% of patients with no initial indication of chemotherapy had an escalation of treatment after ODx for adjuvant chemotherapy. The analysis of the whole population shows a correlation of the lobular histologic type with low RS in univariate or multivariate analysis. Conclusion: RS is clearly prognostic for ILC and IDC. The predictive value of chemotherapy benefit was prospectively demonstrated for IDC, but not so clearly for ILC. In the PONDx cohort, despite a larger size of tumors, the RS of ILC was lower showing different biological features among the gene studied by ODx. The impact on decision making of ODx was similar for ILC and IDC, showing the interest of genomic assay in decision making independently from histologic subtypes (between ILC and IDC).
Citation Format: Gaëlle Douchet, Elsa Curtit, Hugues Bourgeois, Sandrine Richard, Sonia Zilberman, Younes Mahi, Joseph Gligorov. Specific aspect of utilization of the prognostic multigene assay for invasive lobular carcinoma at early stage: Oncotype Dx in the prospective French cohort PONDx [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P2-11-13.
Abstract P2-12-04: Efficacy of intravenous (IV) NEPA and oral NEPA, fixed NK1/5-HT3 receptor antagonist (RA) combination agents, for prevention of chemotherapy-induced nausea and vomiting (CINV) following anthracycline-cyclophosphamide (AC)-based chemotherapy
Authors: Aapro Matti , Schwartzberg Lee 
Published: March 2020

Abstract
Background: The antiemetic guideline-based standard of care for prevention of CINV in patients receiving AC-based chemotherapy is the combination of an NK1 RA, a 5-HT3 RA, and dexamethasone (DEX). An IV formulation of NEPA (fixed combination of the NK1 RA, fosnetupitant and 5-HT3 RA, palonosetron) was recently approved in the United States. Two studies were completed in patients receiving cisplatin (Phase 3) or AC (Phase 3b) to assess the safety of IV NEPA, with specific attention paid to injection-site/hypersensitivity reactions as such events have occurred with other NK1 RAs, particularly in the AC setting. No treatment-related injection-site reactions were reported in &gt;1300 infusions of IV NEPA. Oral NEPA was previously shown to be superior to palonosetron in a Phase 3 AC study. This analysis presents the efficacy data of IV NEPA and oral NEPA in the AC setting.
Methods: Data is compiled from the IV NEPA Phase 3b study as well as from an oral NEPA registration study in females with breast cancer undergoing AC-based chemotherapy. IV NEPA was administered as a single 30-minute infusion and oral NEPA was given as a single capsule 60 minutes prior to AC. Patients also received DEX prior to AC on Day 1 only. Complete response (CR: no emesis/no rescue medication) rates are summarized for the acute (Day 1), delayed (Days 2-5) and overall (Days 1-5) phases of Cycle 1 for each treatment/study and also pooled for oral NEPA across the 2 studies. No formal statistical comparisons were performed.
Results: Patient characteristics were similar in both studies. CR rates were comparable for IV NEPA and oral NEPA in the individual studies as well as with oral NEPA when pooled across the 2 studies (Table).
Cycle 1 Complete Response IV NEPA StudyOral NEPA Study Pooled Studies % Patients IV NEPAOral NEPAOral NEPAOral NEPA(N = 200)(N = 202)(N = 708)(N = 910)Acute (0-24 h)86.588.688.388.4Delayed (25-120 h)75.578.776.476.9Overall (0-120 h)73.077.273.974.6
Conclusions: Both IV and oral formulations of NEPA in combination with DEX represent guideline-compliant single-dose antiemetic agents that are highly effective over 5 days in patients receiving AC-based chemotherapy.
Citation Format: Matti Aapro, Lee Schwartzberg. Efficacy of intravenous (IV) NEPA and oral NEPA, fixed NK1/5-HT3 receptor antagonist (RA) combination agents, for prevention of chemotherapy-induced nausea and vomiting (CINV) following anthracycline-cyclophosphamide (AC)-based chemotherapy [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P2-12-04.
Abstract P2-12-15: Efficacy of Lymphdiaral™ in breast cancer patients with lymphedema
Authors: Younus Jawaid , Black Morgan , Kligman Lyn , Leung Brenda 
Published: March 2020

Abstract
Background: Lymphedema has been a prevalent and often severe side effect for patients receiving treatment for breast cancer typically resulting in physical and psychosocial distress as well as decreased quality of life. With no widely effective or safe drug treatment(s) for lymphedema, this study aimed to assess the efficacy of combined Lymphdiaral™ drops and ointment for treatment-related lymphedema. Methods: This open label, randomized, parallel-group trial ran over 12 weeks with a final follow-up visit at 24 weeks. One hundred and thirty-four (n = 134) patients were consented to the study. Of these, 119 patients were randomized to either standard care group (compression garment) or treatment group (compression garment plus Lymphdiaral™ drops and ointment) and follow-up data was obtained. The primary objective was the reduction in lymphedema as measured by change in arm volume. Results: The values for the arm volumes did not show a statistically significant decrease in both the standard care or treatment groups. Additionally, there was no statistical difference in arm volume reduction between the groups. Conclusions: This first randomized trial shows, that the homeopathic drug combination of Lymphdiaral™ drops and ointment does not improve lymphedema in breast cancer patients.
Citation Format: Jawaid Younus, Morgan Black, Lyn Kligman, Brenda Leung. Efficacy of Lymphdiaral™ in breast cancer patients with lymphedema [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P2-12-15.
Abstract P2-15-11: A phase II trial of genexol-PM and doxorubicin in patients with advanced Her-2 negative breast cancer
Authors: Cho Eun Kyung , Yun Hyo Yeon , Kim Yun Yeong , Jeon Yong Soon , Park Heungkyu 
Published: March 2020

Abstract
Background: Genexol PM is a lyophilized polymeric micellar formulation of paclitaxel that delivers a higher paclitaxel dose with lower vehicle-related toxicities than conventional paclitaxel formulations. This study was designed to evaluate the efficacy and safety of genexol- PM and doxorubicin combination in advanced Her-2 negative Breast cancer as first line treatment.
Methods: Patients with advanced Her-2 negative Breast cancer received Genexol-PM at 260mg/m2 on day 1 and doxorubicin 50mg/m2 on day 1 of 3-week interval cycle. Six to nine cycles of combination chemotherapy were planned unless there was disease progression. The primary endpoint was objective response rate.
Results: Thirty patients received this combination chemotherapy with a median 6cycles per patient (range 1-9). The objective response rate was 67% with disease control rate 87%, Median duration of response was 5.5months (95%CI 3.0-8.1months). Median progression free survival was 7.4 months (95%CI 5.3-9.6months) and overall survival 38.7months (95%CI 21.4-55.9months). The common toxicities were alopecia(93%), peripheral neuropathy(60%), nausea(57%), neutropenia(47%). The most common G3/4 toxicities were neutropenia(43%) and neutropenic fever(27%). There was no treatment related mortality.
Conclusion: Genexol-PM, CrEL-free paclitaxel, in combination with doxorubicin demonstrated favorable antitumor activity in advanced Her-2 negative breast cancer. The most common G3/4 toxicities was neutropenia but it was manageable.
Citation Format: Eun Kyung Cho, Hyo Yeon Yun, Yun Yeong Kim, Yong Soon Jeon, Heungkyu Park. A phase II trial of genexol-PM and doxorubicin in patients with advanced Her-2 negative breast cancer [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P2-15-11.